Growth leadership Recent C-suite appointments signal leadership transition and potential strategic realignment. Sales opportunities could arise from engaging the new CEO and Chairman to discuss long-term AI Eye Screening contracts, expansion plans, and global deployments.

Global expansion Active international footprint with prior South Africa collaborations and a mission to screen every eye worldwide. Target healthcare providers and payers in underserved regions for EyeArt AI deployments, teleophthalmology partnerships, and funded screening programs.

AI driven Strong emphasis on AI Eye Screening and Predictive Biomarkers opens opportunities with hospitals, clinics, and health networks seeking autonomous screening, risk stratification, and population health management solutions for diabetic retinopathy and related conditions.

Funding & growth Current revenue range and substantial funding indicate room for scalable partnerships, including pilot programs, co-development with device manufacturers, and multi-site deployments with revenue-sharing or subscription-based models.

Strategic partnerships Past collaborations with ophthalmology associations and insurers point to a favorable route for multi-stakeholder deals with healthcare networks, discovery health-type partners, and payer programs to expand access to AI-driven eye screening.